Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Compassionate Use of Remdesivir in Covid-19

    Research output: Contribution to journalLetterResearchpeer-review

  2. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Remdesivir til behandling af COVID-19-pneumoni

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Roy F Chemaly
  • Sunwen Chou
  • Hermann Einsele
  • Paul Griffiths
  • Robin Avery
  • Raymund R Razonable
  • Kathleen M Mullane
  • Camille Kotton
  • Jens Lundgren
  • Takashi E Komatsu
  • Peter Lischka
  • Filip Josephson
  • Cameron M Douglas
  • Obi Umeh
  • Veronica Miller
  • Per Ljungman
  • Resistant Definitions Working Group of the Cytomegalovirus Drug Development Forum
View graph of relations

Despite advances in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid organ and hematopoietic cell transplant recipients. CMV infection may fail to respond to commercially available antiviral therapies, with or without demonstrating genotypic mutation(s) known to be associated with resistance to these therapies. This lack of response has been termed "resistant/refractory CMV" and is a key focus of clinical trials of some investigational antiviral agents. To provide consistent criteria for future clinical trials and outcomes research, the CMV Resistance Working Group of the CMV Drug Development Forum (consisting of scientists, clinicians, regulatory officials, and industry representatives from the United States, Canada, and Europe) has undertaken establishing standardized consensus definitions of "resistant" and "refractory" CMV. These definitions have emerged from the Working Group's review of the available virologic and clinical literature and will be subject to reassessment and modification based on results of future studies.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Issue number8
Pages (from-to)1420-1426
Number of pages7
Publication statusPublished - 8 Apr 2019

Bibliographical note

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail:

    Research areas

  • clinical trials, cytomegalovirus, definitions, refractory, resistance

ID: 55142566